Literature DB >> 19560673

Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus:oralvs.parenteral; home vs. hospital.

Silvano Esposito1, Sebastiano Leone, Ester Petta, Silvana Noviello, Filomena Ianniello.   

Abstract

Although meticillin-resistant Staphylococcus aureus (MRSA) is recognized as a significant cause of nosocomial infections, it is also becoming an increasingly common cause of infections in the community. Overall, the most common infections caused by MRSA are those involving the skin and skin structures. These infections are difficult to treat and are associated with high morbidity and substantial cost. This article summarizes the current oral and parenteral therapeutic options, of which there are several, and the optimal site of care for the management of these infections. Defining the severity of the illness is central to improving the decision-making process about the route of administration and site of care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19560673     DOI: 10.1016/S0924-8579(09)70547-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

Review 1.  Distribution of genes encoding tetracycline resistance and aminoglycoside modifying enzymes in Staphylococcus aureus strains isolated from a burn center.

Authors:  M Emaneini; R Bigverdi; D Kalantar; S Soroush; F Jabalameli; B Noorazar Khoshgnab; P Asadollahi; M Taherikalani
Journal:  Ann Burns Fire Disasters       Date:  2013-06-30

2.  Detection of tetracycline resistance genes, aminoglycoside modifying enzymes, and coagulase gene typing of clinical isolates of Staphylococcus aureus in the Southwest of Iran.

Authors:  Seyed Sajjad Khoramrooz; Samin Alipoor Dolatabad; Fatemeh Mostafapour Dolatabad; Masoud Marashifard; Mehdi Mirzaii; Hossein Dabiri; Azam Haddadi; Seyed Mohammadreza Rabani; Hamid Reza Ghaffarian Shirazi; Davood Darban-Sarokhalil
Journal:  Iran J Basic Med Sci       Date:  2017-08       Impact factor: 2.699

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.